Lilly and Boehringer Ingelheim will now be able to promote their drug Jardiance in the US as a way for diabetes patients to reduce their risk of having a heart attack or stroke.
New drugs from Eli Lilly have produced a strong showing in the first quarter, in what could be a key year for a company still recovering from patent expiry of its former blockbuster antidep